Analyst Price Targets — RPRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 27, 2026 6:43 pm | — | Seaport Global | $50.00 | $46.21 | StreetInsider | Royalty Pharma (RPRX) PT Raised to $50 at TD Cowen |
| February 12, 2026 1:14 pm | Terence Flynn | Morgan Stanley | $61.00 | $44.71 | TheFly | Royalty Pharma price target raised to $61 from $56 at Morgan Stanley |
| January 30, 2026 9:40 am | Ashwani Verma | UBS | $49.00 | $40.86 | TheFly | Royalty Pharma upgraded to Buy from Neutral at UBS |
| December 11, 2025 3:12 pm | — | Leerink Partners | $45.00 | $38.22 | StreetInsider | Royalty Pharma (RPRX) PT Raised at TD Cowen; 'Best Ideas 2026: Unique Business' |
| September 30, 2025 9:10 am | — | Goldman Sachs | $42.00 | $35.25 | TheFly | Royalty Pharma initiated with a Buy at Goldman Sachs |
| July 10, 2025 12:34 pm | Terence Flynn | Morgan Stanley | $54.00 | $36.14 | TheFly | Royalty Pharma price target raised to $54 from $51 at Morgan Stanley |
| September 4, 2024 7:44 am | Chris Shibutani | Goldman Sachs | $51.00 | $29.16 | StreetInsider | Goldman Sachs Reiterates Buy Rating on Royalty Pharma (RPRX) |
| July 11, 2024 8:15 am | Terence Flynn | Morgan Stanley | $51.00 | $25.73 | TheFly | Royalty Pharma price target raised to $51 from $48 at Morgan Stanley |
| June 7, 2024 4:57 am | Chris Shibutani | Goldman Sachs | $50.00 | $27.09 | StreetInsider | Royalty Pharma (RPRX) PT Raised to $50 at Goldman Sachs |
| June 3, 2024 8:53 am | Ashwani Verma | UBS | $28.00 | $27.35 | TheFly | Royalty Pharma downgraded to Neutral from Buy at UBS |
Latest News for RPRX
Royalty Pharma plc (RPRX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty business in Asia. Ken joins Royalty Pharma from Morgan Stanley, where he was Head of Asia Pacific Healthcare Investment Banking.
NEW YORK and VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Zymeworks Inc. (Nasdaq: ZYME) today announced an agreement for $250 million in funding from Royalty Pharma in the form of a non-recourse royalty-backed note with repayments due from 30% of worldwide tiered royalties on Ziihera® (zanidatamab-hrii) owed to Zymeworks from Jazz Pharmaceuticals (Jazz) and…
Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) was the target of a significant drop in short interest in the month of February. As of February 13th, there was short interest totaling 13,443,797 shares, a drop of 49.2% from the January 29th total of 26,462,455 shares. Based on an average trading volume of 4,434,841 shares,
NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen's 46th Annual Health Care Conference on March 3, 2026 at 1:10 p.m. ET.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RPRX.
U.S. House Trading
No House trades found for RPRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.